RARE · Ultragenyx Pharmaceutical Inc.
$16.08
+2.75% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
69.4
Dividend yield
0.0%
Beta
0.35
Avg volume
4M
Employees
1K
Daily Change %
2.75%
5 Days Change
9.70%
10 Days Change
6.90%
30 Days Change
7.19%
60 Days Change
-37.99%
Month to Day Change
8.14%
Year to Day Change
-30.65%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RARE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
UBS
Neutral$16.00
+2.2% vs priceBarclays
Overweight$35.00
+123.6% vs priceMorgan Stanley
Equal-Weight$20.00
+27.8% vs priceCitigroup
Buy$32.00
+104.5% vs priceGoldman Sachs
Neutral$19.00
+21.4% vs priceJP Morgan
Neutral$36.00
+130.0% vs priceJefferies
Buy$28.00
+78.9% vs priceWells Fargo
Overweight$18.00
+15.0% vs priceRBC Capital
Outperform$40.00
+155.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | UBS | Initiates | Neutral | $0.00 → $16.00 |
| 2026-09-21 | Evercore ISI Group | Maintains | In-Line | $16.00 → $18.00 |
| 2026-09-21 | Barclays | Maintains | Overweight | $32.00 → $35.00 |
| 2026-09-18 | Morgan Stanley | Maintains | Equal-Weight | $18.00 → $20.00 |
| 2026-09-18 | Citigroup | Maintains | Buy | $31.00 → $32.00 |
| 2026-09-18 | Canaccord Genuity | Maintains | Buy | $37.00 → $39.00 |
| 2026-09-18 | Cantor Fitzgerald | Maintains | Overweight | $33.00 → $39.00 |
| 2026-09-17 | Citigroup | Maintains | Buy | $28.00 → $31.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 9.4% below the 50-day MA ($17.74).
- bearish: Price vs 200-day MA: Trading 30.2% below the 200-day MA ($23.04).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.36) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($12.88) and high ($36.54).
RARE Price Chart
Loading chart for RARE…
Fundamentals
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.